Hospital-acquired infections, also known as nosocomial infections, are acquired by patients in the hospitals or healthcare facilities. Urinary tract infections, bloodstream infections, surgical-site infections, Clostridium difficile associated diarrhea, and pneumonia are examples of nosocomial infections.
The hospital infection therapeutics market is increasing at a significant rate, due to high susceptibility of neonatal population in healthcare setting and high occurrence of numerous hospital infections. Increasing incidences of hospital infections, high number of pipeline drug molecules for specific treatment of healthcare associated infections and high unaddressed needs in most of the countries are some of the factors providing ample opportunities for the hospital infection therapeutics market to grow in the coming years.
North America led the demand for hospital infection therapeutics market in 2017. The high prevalence of nosocomial infections has been identified as the key factor that has been driving the demand for infection therapeutics in North America and is projected to continue to do so throughout the forecast period. Although North America will remain the leading regional market for hospital infection therapeutics, it is Asia Pacific, which will present the most promising growth opportunities to this market in the near future.
In 2018, the global Hospital Infection Therapeutics market size was 2700 million US$ and it is expected to reach 3840 million US$ by the end of 2025, with a CAGR of 4.5% during 2019-2025.
This report focuses on the global Hospital Infection Therapeutics status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Hospital Infection Therapeutics development in United States, Europe and China.
The key players covered in this study
Johnson & Johnson Services
Bristol Myers Squibb Company
Market segment by Type, the product can be split into
Market segment by Application, split into
Hospital Acquired Pneumonia
Surgical Site Infections
Urinary Tract Infection
Market segment by Regions/Countries, this report covers
Central & South America
The study objectives of this report are:
To analyze global Hospital Infection Therapeutics status, future forecast, growth opportunity, key market and key players.
To present the Hospital Infection Therapeutics development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.
In this study, the years considered to estimate the market size of Hospital Infection Therapeutics are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.